新辅助FOLFIRINOX或吉西他滨/白蛋白紫杉醇后临床与病理缓解与胰腺癌切除术后生存结局的关联
该多中心回顾性研究分析了274例接受新辅助化疗(FOLFIRINOX或吉西他滨/白蛋白紫杉醇)后行根治性切除术的胰腺导管腺癌患者,发现生化缓解(CA19-9下降≥50%)和病理缓解(pCR/pPR/pLR)与更优的总生存、局部无复发生存和无转移生存相关,而两种化疗方案的生存结局无差异。
要点
- CA19-9下降≥50%者中位OS为42.3个月,下降<50%者为24.3个月(P<0.001)。
- 病理完全缓解(pCR)者OS未达到,部分缓解(pPR)为40.3个月,有限缓解(pLR)为26.1个月(P<0.001)。
- FOLFIRINOX与吉西他滨/白蛋白紫杉醇在OS、L-RFS和MFS上无差异。
核心结论
- 新辅助化疗后生化、病理和临床缓解的改善与胰腺导管腺癌切除术后OS、L-RFS和MFS的改善相关。
- FOLFIRINOX与吉西他滨/白蛋白紫杉醇新辅助化疗的生存结局相似。
研究设计与样本
- 多中心回顾性分析,纳入7家学术医疗中心收治的274例接受新辅助化疗后行根治性切除术的胰腺导管腺癌患者。
主要发现
- 46.4%为交界可切除,25.5%为局部进展期,83.2%为胰头/颈部肿瘤;静脉切除占34.7%,30天死亡率为2.2%。
- R0切除率为82.5%,pCR率为6%;中位OS为32个月,3年OS为46.3%,5年OS为30.3%。
- CA19-9下降≥50% vs <50%:中位OS 42.3 vs 24.3个月(P<0.001),L-RFS 27.3 vs 14.1个月(P=0.042),MFS 29.3 vs 13个月(P=0.047)。
- 病理缓解pCR vs pPR vs pLR:中位OS未达到 vs 40.3 vs 26.1个月(P<0.001),L-RFS未达到 vs 24.5 vs 21.4个月(P=0.044),MFS未达到 vs 23.7 vs 20.2个月(P=0.017)。
- FOLFIRINOX与吉西他滨/白蛋白紫杉醇组间L-RFS、MFS和OS无差异。
临床怎么用
- 新辅助化疗后CA19-9下降≥50%和病理缓解(尤其pCR)可提示更优生存,可用于预后评估。
- FOLFIRINOX与吉西他滨/白蛋白紫杉醇在新辅助治疗中生存结局相似,方案选择可综合考虑其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy. BACKGROUND: Newer multiagent NAC regimens have resulted in improved clinical and pathological responses in PDAC; however, the effects of these responses on survival outcomes remain unknown. METHODS: Clinicopathological and survival data of PDAC patients treated at 7 academic medical centers were analyzed. Primary outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-free survival (MFS) associated with biochemical (CA 19-9 decrease ≥50% vs <50%) and pathological response (complete, pCR; partial, pPR or limited, pLR) following NAC. RESULTS: Of 274 included patients, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancreatic head/neck tumors. Vein resection was performed in 34.7% and 30-day mortality was 2.2%. R0 and pCR rates were 82.5% and 6%, respectively. Median, 3-year, and 5-year OS were 32 months, 46.3%, and 30.3%, respectively. OS, L-RFS, and MFS were superior in patients with marked biochemical response (CA 19-9 decrease ≥50% vs <50%; OS: 42.3 vs 24.3 months, P < 0.001; L-RFS-27.3 vs 14.1 months, P = 0.042; MFS-29.3 vs 13 months, P = 0.047) and pathological response [pCR vs pPR vs pLR: OS- not reached (NR) vs 40.3 vs 26.1 months, P < 0.001; L-RFS-NR vs 24.5 vs 21.4 months, P = 0.044; MFS-NR vs 23.7 vs 20.2 months, P = 0.017]. There was no difference in L-RFS, MFS, or OS between patients who received FLX or GNP. CONCLUSION: This large, multicenter study shows that improved biochemical, pathological, and clinical responses associated with NAC FLX or GNP result in improved OS, L-RFS, and MFS in PDAC. NAC with FLX or GNP has similar survival outcomes.
引用
- Macedo FI, Ryon E, Maithel SK, et al. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Ann Surg. 2019. PMID: 31283563. doi:10.1097/SLA.0000000000003468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。